Allergy Therapeutics PLC, a biotechnology company specializing in allergy vaccines, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Corporate Broker. The appointment is effective immediately. The company's CEO, Manuel Llobet, and CFO, Shaun Furlong, can be contacted for further information. Cavendish Capital Markets Limited will serve as the Nominated Adviser and Broker, with a team including Geoff Nash, Giles Balleny, Seamus Fricker, Rory Sale, Nigel Birks, and Tamar Cranford Smith. ICR Consilium will handle media inquiries. Allergy Therapeutics is known for its focus on developing and commercializing allergy vaccines.